letrozole + chromium

Letrozole + chromium is an investigational combination therapy consisting of letrozole, a selective nonsteroidal aromatase inhibitor, and chromium, typically administered as chromium picolinate. Letrozole works by inhibiting the aromatase enzyme, thereby reducing estrogen synthesis and is primarily used in the treatment of hormone receptor-positive breast cancer in postmenopausal women. Chromium is an essential trace element that may enhance insulin sensitivity and has been studied for its potential to improve metabolic parameters. The combination is being explored for ovulation induction in women with polycystic ovary syndrome (PCOS), based on evidence suggesting that chromium may potentiate the therapeutic effect of letrozole on pituitary hormones (FSH and LH), improve ovulation rates, normalize estrogen levels, and enhance endometrial thickness related to ovulation[1][2]. This combination remains under clinical investigation.